Cholangiocarcinoma is a malignant tumor of the digestive system, and its survival period is related to the patient’s own condition and the early and late detection of the disease, so it needs to be analyzed on a case-by-case basis and cannot be generalized. The incidence of cholangiocarcinoma is relatively insidious, and the probability of patients who can be diagnosed at early detection is low, only 15%, which can be treated by surgical resection, and the five-year survival after surgery can be about 75%. Most patients with intermediate or advanced cholangiocarcinoma cannot be treated by surgery and can only improve their survival quality by other means, and their survival period is often shorter, generally 3-6 months from diagnosis to death. In severe cases, if acute obstructive suppurative cholangitis is complicated, it is easy to cause infectious shock, and the disease is more dangerous and has a poor prognosis with rapid progress. In addition, patients with cholangiocarcinoma must pay attention to rest after surgery to avoid the possibility of recurrence due to the decrease of immunity caused by fatigue.